ClinicalTrials.gg

Program

ontunisertib

Also written as “Ontunisertib”, “AGMB-129” and “[14C]ontunisertib”.

Its studies are mostly in Crohn Disease, led by 2 companies.

Furthest: phase 2, since Apr 25, 20237 company-led studies, 2 open or runningNext primary completion: Dec 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agomab Therapeutics NV62 open or runningphase 2since Apr 25, 2023Apr 25, 2023Dec 31, 2028phase 2 · NCT07683325
Origo Biopharma10 open or runningphase 1since Jun 18, 2021Jun 18, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 18, 2021First study: phase 1 study in Healthy VolunteersNew to Origo BiopharmaOrigo Biopharma · NCT04933565 · 81 enrolled · Spain
  2. Apr 25, 2023Agomab Therapeutics NV's first study: phase 2 study in Fibrostenotic Crohn's DiseaseNew to Agomab Therapeutics NVAgomab Therapeutics NV · NCT05843578 · 103 enrolled · United States, Austria, Canada and more
  3. Jun 30, 2023Phase 1 study in Healthy VolunteersAgomab Therapeutics NV · NCT05937386 · 14 enrolled · Belgium
  4. Apr 30, 2024Phase 1 study in Healthy VolunteersAgomab Therapeutics NV · NCT06397508 · 25 enrolled · Belgium
  5. Jul 28, 2025Phase 1 study in Fibrostenotic Crohn's DiseaseAgomab Therapeutics NV · NCT07118878 · 30 enrolled · Belgium
  6. Jun 12, 2026Phase 1 study in Fibrostenotic Crohn's DiseaseAgomab Therapeutics NV · NCT07672574 · 8 planned · United Kingdom
  7. Jun 24, 2026Phase 2 study in Fibrostenotic Crohn's DiseaseAgomab Therapeutics NV · NCT07683325 · 320 planned · United States, Serbia, United Kingdom

Ahead

  1. Dec 31, 2028Primary completion: phase 2 study in Fibrostenotic Crohn's DiseaseAgomab Therapeutics NV · NCT07683325

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07683325Fibrostenotic Crohn's Disease · United States, Serbia, United Kingdom2RecruitingAgomab Therapeutics NVDec 31, 2028320
NCT07672574Fibrostenotic Crohn's Disease · United Kingdom1RecruitingAgomab Therapeutics NVSep 26, 20268
NCT07118878Fibrostenotic Crohn's Disease · Belgium1CompletedAgomab Therapeutics NVSep 15, 202530
NCT06397508Healthy Volunteers · Belgium1CompletedAgomab Therapeutics NVMay 8, 202425
NCT05937386Healthy Volunteers · Belgium1CompletedAgomab Therapeutics NVSep 6, 202314
NCT05843578Fibrostenotic Crohn's Disease · United States, Austria, Canada and more2CompletedAgomab Therapeutics NVJun 20, 2026103
NCT04933565Healthy Volunteers · Spain1CompletedOrigo BiopharmaDec 12, 202281

How it is read

Names in the registry

  • “Ontunisertib”, 4 entries
  • “AGMB-129”, 4 entries
  • “[14C]ontunisertib”, 2 entries
  • “ORG-129”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.